New metaanalysis reveals broad benefits This new eRxAcademy summary highlights growing evidence that GLP1 therapies deliver meaningful cardiovascular and renal benefitswithout introducing additional safety risks
I will always maintain that selling women inadequately studied products under the guise of closing the gaps in health care and using misleading language is predatory and misogynistic, as misinformation robs women of agency
Advantages include: Ease of use and integration into a care routine Targeted action on the scalp Generally favorable safety profile Availability without prescription for cosmetic formulations To optimize skin penetration, some users combine topical peptide application with scalp microneedling (dermarolling)
Nevertheless, even the most effective marketed incretin, the GLP-1/GIP dual agonist tirzepatide, produces a maximum HbA1c reduction of ~2.6%, with fewer than half of participants in the SURPASS trials reaching normoglycemia (HbA1c 10%), vehicle-treated animals lost ~40% of body weight over 3 months, consistent with prior reports showing comparable reductions from ~40 g at week 10 to ~25 g by week 20 19
Severe but rare side effects can include pancreatitis, medullary thyroid cancer, acute kidney injury, and worsening diabetes related retinopathy
TriReduction is an advanced copper peptide system that works best in conjunction with hydroxy acids
